# US 2013/0274229 A1 · Enhanced anti-influenza agents conjugated with anti-inflammatory activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274229 A1
- Document ID: US20130274229A1
- Status: Published application
- Kind: A1
- Application number: 13/836,356
- Filed: 2013-03-15
- Published: 2013-10-17
- Earliest claimed: 2012-04-14
- Assignees: Academia Sinica
- Applicants: Academia Sinica
- Inventors: Chi-Huey Wong; Jim-Min Fang; Kung-Cheng Liu; Jia-Tsrong Jan; Yih-Shyun E. Cheng; Ting-Jen R. Cheng
- Web page: https://patentgrep.com/patent/US20130274229A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 31/351: not condensed with another ring
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/16: for influenza or rhinoviruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 309/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.

## Claims

### Claim 1

A chimeric drug compound comprising:
a first moiety and a second moiety, wherein the first moiety is an anti-influenza agent and the second moiety is an anti-inflammatory agent, wherein the first and second moieties are conjugated via a linker as in Formula (A).

### Claim 2 (depends on 1)

The compound of claim 1, wherein the anti-inflammatory agent is a non-steroidal anti-inflammatory agent.

### Claim 3 (depends on 2)

The compound of claim 2, wherein the non-steroidal anti-inflammatory agent is an acid anti-inflammatory agent.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the anti-influenza agent is a neuraminidase inhibitor.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the anti-influenza agent is zanamivir (ZA), phosphono-zanamivir (PZA), oseltamivir (OS), tamiphosphor (TP), or peramivir (PE), or a derivative thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein one or more of the anti-influenza agents are conjugated with one or more of the anti-inflammatory agents via the linker.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the linker comprises an optionally substituted C1-20 hydrocarbon chain or optionally substituted cycloalkyl, wherein one or more carbon units are replaced with NRN, O or S, wherein RN is hydrogen, optionally substituted alkyl, or a nitrogen protecting group.

### Claim 8 (depends on 6)

The compound of claim 6, wherein the linker is cleavable by an esterase.

### Claim 9 (depends on 6)

The compound of claim 6, wherein the linker is not cleavable by an esterase.

### Claim 10 (depends on 6)

The compound of claim 6, wherein the linker is cleavable in lysosome.

### Claim 11 (depends on 6)

The compound of claim 6, wherein the linker is not cleavable in lysosome.

### Claim 12 (depends on 5)

The compound of claim 5, wherein the compound is of formula (I) or (II):
or a pharmaceutically acceptable salt thereof;
wherein:
X1 is —O—, —O(C═O)—, —NH—, —NHCO—, —O(C═O)NH—, —O(C═S)NH—, —NH(C═O)NH—, Or —NH(C═S)NH—;
L is a linker selected from the group consisting of a bond, —(CH2)n—, —(CH2)nO—, —O(CH2)n—, —(CH2)n—C(O)—, —(CH2)n—NH—, —NH—(CH2)n—, —C(O)(CH2)n—, —(CH2)n—NHC(O)—, —C(O)(CH2)n—NHC(O)—, (CH2)nSCH2C(O)—, and —(CH2CH2O)m—;
n is an integer from 1 to 8, inclusive;
m is an integer from 1 to 4, inclusive;
X1 is covalently linked to L;
Y is a non-steroidal anti-inflammatory agent selected from the group consisting of aceclofenac, acemetacin, acetyl-sailcylic acid, 5-aminoacetylsalicylic acid, aldlofenac, amfenac, bendazac, benoxaprofen, bermoprofen, bromfenac, 5-bromosalicylic acid acetate, bucloxic acid, butibufen, caffeic acid, carprofen, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, 3,4-dihydroxybenzoic acid, enfenamic acid, etodolac, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, 1-hydroxynaphthoic acid, ibufenac, ibuprofen, indomethacin, indoprofen, isofezolac, isoxepac, ketoprofen, ketorolac, loxoprofen, meclofenamic acid, mefenamic acid, mesalazine, 3,4-methylenedioxycinnamic acid, metiazinic acid, mofezolac, montelukast, mycophenolic acid, naproxen, niflumic acid, olsalazine, oxaceprol, oxaprozin, pyrazolac, pirprofen, pranoprofen, protizinic acid, sulindac, suprofen, suxibutazone, tiaprofenic acid, tinoridine acid, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, and zomepirac;
Y is covalently linked to L via an acid group in the non-steroidal anti-inflammatory agent;
B is an azido, a hydroxyl, an unsubstituted or substituted amino, or an unsubstituted or substituted guanidino, or the corresponding salts with an anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulfate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, and gluconate;
each instance of R1 and R5 is, independently, hydrogen or optionally substituted C1-6 alkyl;
each instance of R2 and R3 is, independently, hydrogen, optionally substituted alkyl, or Optionally substituted acyl group; and
R4 is —COCH3, —COCF3, —SO2CH3 or —SO2CF3.

### Claim 13 (depends on 5)

The compound of claim 5, wherein the compound is of formula (III) or (IV):
or a pharmaceutically acceptable salt thereof;
wherein:
X2 is —O— or —NH—;
X2 is covalently linked to L;
L is a linker selected from the group consisting of a bond, —(CH2)n—, —(CH2)nO—, —O(CH2)n—, —(CH2)n—C(O)—, —(CH2)n—NH—, —NH—(CH2)n—, —C(O)(CH2)n—, —(CH2)n—NHC(O)—, —C(O)(CH2)n—NHC(O)—, (CH2)nSCH2C(O)—, and —(CH2CH2O)m—;
n is an integer from 1 to 8;
m is an integer from 1 to 4;
Y is a non-steroidal anti-inflammatory agent selected from the group consisting of aceclofenac, acemetacin, acetyl-sailcylic acid, 5-aminoacetylsalicylic acid, aldlofenac, amfenac, bendazac, benoxaprofen, bermoprofen, bromfenac, 5-bromosalicylic acid acetate, bucloxic acid, butibufen, caffeic acid, carprofen, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, 3,4-dihydroxybenzoic acid, enfenamic acid, etodolac, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, 1-hydroxynaphthoic acid, ibufenac, ibuprofen, indomethacin, indoprofen, isofezolac, isoxepac, ketoprofen, ketorolac, loxoprofen, meclofenamic acid, mefenamic acid, mesalazine, 3,4-methylenedioxycinnamic acid, metiazinic acid, mofezolac, montelukast, mycophenolic acid, naproxen, niflumic acid, olsalazine, oxaceprol, oxaprozin, pyrazolac, pirprofen, pranoprofen, protizinic acid, sulindac, suprofen, suxibutazone, tiaprofenic acid, tinoridine acid, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, and zomepirac;
Y is covalently linked to L via an acid group in the non-steroidal anti-inflammatory agent;
B is an azido, a hydroxyl, an unsubstituted or substituted amino, or an unsubstituted or substituted guanidino, or the corresponding salts with an anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulfate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, and gluconate;
each instance of R2 and R3 is, independently, hydrogen, optionally substituted alkyl, or Optionally substituted acyl group;
R4 is —COCH3, —COCF3, —SO2CH3 or —SO2CF3; and
R6 is hydrogen or optionally substituted C1-6 alkyl.

### Claim 14 (depends on 5)

The compound of claim 5, wherein the compound is of formula (V) or (VI):
or a pharmaceutically acceptable salt thereof;
wherein:
X1 is —O—, —O(C═O)—, —NH—, —NHCO—, —O(C═O)NH—, —O(C═S)NH—, —NH(C═O)NH—, Or —NH(C═S)NH—;
L is a linker selected from the group consisting of a bond, —(CH2)n—, —(CH2)nO—, —O(CH2)n—, —(CH2)n—C(O)—, —(CH2)n—NH—, —NH—(CH2)n—, —C(O)(CH2)n—, —(CH2)n—NHC(O)—, —C(O)(CH2)n—NHC(O)—, (CH2)nSCH2C(O)—, and —(CH2CH2O)m—;
n is an integer from 1 to 8;
m is an integer from 1 to 4;
X1 is covalently linked to L;
Y is a non-steroidal anti-inflammatory agent selected from the group consisting of aceclofenac, acemetacin, acetyl-sailcylic acid, 5-aminoacetylsalicylic acid, aldlofenac, amfenac, bendazac, benoxaprofen, bermoprofen, bromfenac, 5-bromosalicylic acid acetate, bucloxic acid, butibufen, caffeic acid, carprofen, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, 3,4-dihydroxybenzoic acid, enfenamic acid, etodolac, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, 1-hydroxynaphthoic acid, ibufenac, ibuprofen, indomethacin, indoprofen, isofezolac, isoxepac, ketoprofen, ketorolac, loxoprofen, meclofenamic acid, mefenamic acid, mesalazine, 3,4-methylenedioxycinnamic acid, metiazinic acid, mofezolac, montelukast, mycophenolic acid, naproxen, niflumic acid, olsalazine, oxaceprol, oxaprozin, pyrazolac, pirprofen, pranoprofen, protizinic acid, sulindac, suprofen, suxibutazone, tiaprofenic acid, tinoridine acid, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, and zomepirac;
Y is covalently linked to L via an acid group in the non-steroidal anti-inflammatory agent;
B is an azido, a hydroxyl, an unsubstituted or substituted amino, or an unsubstituted or substituted guanidino, or the corresponding salts with an anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulfate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, and gluconate;
each instance of R1, R5 and R6 is, independently, hydrogen or optionally substituted C16 alkyl;
each instance of R2 and R3 is, independently, hydrogen, optionally substituted alkyl, or Optionally substituted acyl group; and
R4 is —COCH3, —COCF3, —SO2CH3 or —SO2CF3.

### Claim 15 (depends on 5)

The compound of claim 5, wherein the compound is of formula (VII) or (VIII):
or a pharmaceutically acceptable salt thereof;
wherein:
Y is a non-steroidal anti-inflammatory agent selected from the group consisting of aceclofenac, acemetacin, acetyl-sailcylic acid, 5-aminoacetylsalicylic acid, aldlofenac, amfenac, bendazac, benoxaprofen, bermoprofen, bromfenac, 5-bromosalicylic acid acetate, bucloxic acid, butibufen, caffeic acid, carprofen, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, 3,4-dihydroxybenzoic acid, enfenamic acid, etodolac, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, 1-hydroxynaphthoic acid, ibufenac, ibuprofen, indomethacin, indoprofen, isofezolac, isoxepac, ketoprofen, ketorolac, loxoprofen, meclofenamic acid, mefenamic acid, mesalazine, 3,4-methylenedioxycinnamic acid, metiazinic acid, mofezolac, montelukast, mycophenolic acid, naproxen, niflumic acid, olsalazine, oxaceprol, oxaprozin, pyrazolac, pirprofen, pranoprofen, protizinic acid, sulindac, suprofen, suxibutazone, tiaprofenic acid, tinoridine acid, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, and zomepirac;
Y is covalently linked to L via an acid group in the non-steroidal anti-inflammatory agent;
each instance of R1, R5 and R6 is, independently, hydrogen or optionally substituted C16 alkyl;
each instance of R2 and R3 is, independently, hydrogen, optionally substituted alkyl, or Optionally substituted acyl group; and
R4 is —COCH3, —COCF3, —SO2CH3 or —SO2CF3.

### Claim 16 (depends on 5)

The compound of claim 5, wherein the compound is of formula (IX) or (X):
or a pharmaceutically acceptable salt thereof;
wherein:
X2 is —O— or —NH—;
X2 is covalently linked to L;
L is a linker selected from the group consisting of a bond, —(CH2)n—, —(CH2)nO—, —O(CH2)n—, —(CH2)n—C(O)—, —(CH2)n—NH—, —NH—(CH2)n—, —C(O)(CH2)n—, —(CH2)n—NHC(O)—, —C(O)(CH2)n—NHC(O)—, (CH2)nSCH2C(O)—, and —(CH2CH2O)m—;
n is an integer from 1 to 8;
m is an integer from 1 to 4;
Y is a non-steroidal anti-inflammatory agent selected from the group consisting of aceclofenac, acemetacin, acetyl-sailcylic acid, 5-aminoacetylsalicylic acid, aldlofenac, amfenac, bendazac, benoxaprofen, bermoprofen, bromfenac, 5-bromosalicylic acid acetate, bucloxic acid, butibufen, caffeic acid, carprofen, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, 3,4-dihydroxybenzoic acid, enfenamic acid, etodolac, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, 1-hydroxynaphthoic acid, ibufenac, ibuprofen, indomethacin, indoprofen, isofezolac, isoxepac, ketoprofen, ketorolac, loxoprofen, meclofenamic acid, mefenamic acid, mesalazine, 3,4-methylenedioxycinnamic acid, metiazinic acid, mofezolac, montelukast, mycophenolic acid, naproxen, niflumic acid, olsalazine, oxaceprol, oxaprozin, pyrazolac, pirprofen, pranoprofen, protizinic acid, sulindac, suprofen, suxibutazone, tiaprofenic acid, tinoridine acid, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, and zomepirac;
Y is covalently linked to L via an acid group in the non-steroidal anti-inflammatory agent;
B is an azido, a hydroxyl, an unsubstituted or substituted amino, or an unsubstituted or substituted guanidino, or the corresponding salts with an anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulfate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, and gluconate;
R4 is —COCH3, —COCF3, —SO2CH3 or —SO2CF3.

### Claim 17 (depends on 5)

The compound of claim 5, wherein the compound is of formula (XI) or (XII):
or a pharmaceutically acceptable salt thereof;
wherein:
X1 is —O—, —O(C═O)—, —NH—, —NHCO—, —O(C═O)NH—, —O(C═S)NH—, —NH(C═O)NH—, Or —NH(C═S)NH—;
X2 is —O— or —NH—;
X1 or X2 is covalently linked to L;
L is a linker selected from the group consisting of a bond, —(CH2)n—, —(CH2)nO—, —O(CH2)n—, —(CH2)n—C(O)—, —(CH2)n—NH—, —NH—(CH2)n—, —C(O)(CH2)n—, —(CH2)n—NHC(O)—, —C(O)(CH2)n—NHC(O)—, (CH2)nSCH2C(O)—, and —(CH2CH2O)m—;
n is an integer from 1 to 8;
m is an integer from 1 to 4;
Y is a non-steroidal anti-inflammatory agent selected from the group consisting of aceclofenac, acemetacin, acetyl-sailcylic acid, 5-aminoacetylsalicylic acid, aldlofenac, amfenac, bendazac, benoxaprofen, bermoprofen, bromfenac, 5-bromosalicylic acid acetate, bucloxic acid, butibufen, caffeic acid, carprofen, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, 3,4-dihydroxybenzoic acid, enfenamic acid, etodolac, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, 1-hydroxynaphthoic acid, ibufenac, ibuprofen, indomethacin, indoprofen, isofezolac, isoxepac, ketoprofen, ketorolac, loxoprofen, meclofenamic acid, mefenamic acid, mesalazine, 3,4-methylenedioxycinnamic acid, metiazinic acid, mofezolac, montelukast, mycophenolic acid, naproxen, niflumic acid, olsalazine, oxaceprol, oxaprozin, pyrazolac, pirprofen, pranoprofen, protizinic acid, sulindac, suprofen, suxibutazone, tiaprofenic acid, tinoridine acid, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, and zomepirac;
Y is covalently linked to L via an acid group in the non-steroidal anti-inflammatory agent;
B is an azido, a hydroxyl, an unsubstituted or substituted amino, or an unsubstituted or substituted guanidino, or the corresponding salts with an anionic counterion selected from the group consisting of chloride, bromide, iodide, acetate, trifluoroacetate, phosphate, diphosphate, nitrate, sulfate, benzenesulfonate, benzoate, salicylate, hydroxynaphthoate, fumarate, maleate, lactate, malate, succinate, tartrate, citrate, glutamate, and gluconate;
each instance of R1 and R7 is, independently, hydrogen or optionally substituted C1-6 alkyl; and
R4 is —COCH3, —COCF3, —SO2CH3 or —SO2CF3.

### Claim 18 (depends on 12)

The compound of claim 12, wherein the compound is selected from the group consisting of:

### Claim 19 (depends on 13)

The compound of claim 13, wherein the compound is selected from the group consisting of:

### Claim 20 (depends on 14)

The compound of claim 14, wherein the compound is selected from the group consisting of:

### Claim 21 (depends on 14)

The compound of claim 14, wherein the compound is selected from the group consisting of:

### Claim 22 (depends on 14)

The compound of claim 14, wherein the compound is selected from the group consisting of:

### Claim 23 (depends on 15)

The compound of claim 15, wherein the compound is selected from the group consisting of:

### Claim 24

A dual-active pharmaceutical composition for simultaneously inhibiting influenza virus and inflammation, the composition comprising:
a compound comprising:
a first moiety and a second moiety, wherein the first moiety is an anti-influenza agent and the second moiety is an anti-inflammatory agent, and wherein the first and second moieties are conjugated via a linker as in Formula (A).
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the anti-influenza agent is an influenza virus neuraminidase inhibitor.

### Claim 26 (depends on 24)

The composition of claim 24, wherein the anti-inflammatory agent is a pro-inflammatory cytokine inhibitor.

### Claim 27 (depends on 24)

The composition of claim 24, wherein the compound inhibits both human and avian influenza virus.

### Claim 28 (depends on 24)

The composition of claim 24, wherein the compound inhibits at least one of H1N1 and H5N1 strains of influenza virus.

### Claim 29 (depends on 25)

The composition of claim 25, wherein the neuraminidase is a wild-type neuraminidase.

### Claim 30 (depends on 25)

The composition of claim 25, wherein the neuraminidase is oseltamivir-resistant.

### Claim 31 (depends on 24)

A method for treating influenza infection in a subject, the method comprising: administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 24.

### Claim 32 (depends on 31)

The method of claim 31, wherein the subject has, is suspected of having, or is at risk for influenza virus infection.
